The objective of this review was to evaluate the potential of tauroursodeoxycholic acid (TUDCA) for neuroprotection in traumatic brain injury (TBI) patients in the neurocritical care setting. Specifically, we surveyed preclinical studies describing the neuroprotective and systemic effects of TUDCA, and the potential therapeutic application of TUDCA. Preclinical studies have provided promising data supporting its use in neurological disease characterized by apoptosis-induced neuronal loss. TUDCA inhibits multiple proteins involved in apoptosis and upregulates cell survival pathways. In addition, TUDCA exhibits anti-inflammatory effects in models of neuroinflammation and attenuates neuronal loss in chronic neurodegenerative diseases. This may be applicable to TBI, which also triggers inflammatory and apoptotic processes. Additionally, preliminary data support the use of pharmacological therapies that reduce apoptosis and inflammation associated with TBI. The anti-apoptotic and anti-inflammatory mechanisms of TUDCA could prove promising in the treatment of TBI. Currently, there are no published data supporting improvement in clinical outcomes of TBI by treatment with TUDCA, but future studies should be considered.
Bibliographical noteFunding Information:
Kyle R. Gronbeck was supported by the University of Minnesota Medical Student Summer Research Grant and the 2015 Medical Student Summer Research Scholarship through the American Academy of Neurology (AAN). Dr. Divani has received research support from Lake Region Medical, Chaska, Minnesota, USA.
© 2016, Springer Science+Business Media New York.
- Blast injury
- Intracerebral hemorrhage
- Intracranial pressure
- Tauroursodeoxycholic acid
- Traumatic brain injury